Full text is available at the source.
Abstract
More than half of heart failure cases occur with preserved ejection fraction (HFpEF).
- HFpEF is influenced by comorbidities such as obesity, hypertension, diabetes, and atrial fibrillation.
- Despite treatments like SGLT2 inhibitors and mineralocorticoid receptor antagonists, morbidity and mortality in HFpEF remain significant.
- GLP1 receptor agonists, originally for type 2 diabetes, have shown benefits in cardiovascular, renal, and metabolic pathways relevant to HFpEF.
- Recent trials indicate that semaglutide improves symptoms and functional capacity, while tirzepatide reduces cardiovascular death or worsening heart failure events.
- Mechanistic evidence points to effects on fluid balance, inflammation, heart structure changes, blood vessel function, and fat tissue quality.
Simplified